LAP, a clinically approved dual-HER2/EGFRtyrosine-kinase inhibitor for breast cancer, offers significant therapeuticadvantages, but its clinical utility is hampered by poor solubilityand systemic side effects. This evidence concerns the gene ERBB2 and breast carcinoma.